Trial Profile
Phase I Trial of a 5-day Regimen of Temodar Plus O6-Benzylguanine (O6-BG) in the Treatment of Patients With Recurrent / Progressive Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Temozolomide (Primary) ; Benzylguanine; Pegfilgrastim
- Indications Glioblastoma
- Focus Adverse reactions
- 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 Additional lead investigator identified as reported by ClinicalTrials.gov, last updated 22 Jan 2009.